Attorney Docket No.: PB60024USw

REMARKS

Claims 1-19 are presented in this application. In this amendment, claim 2 has been cancelled, and claims 1 and 3-19 have been amended. Claims 1 and 3-19 have been amended to place them in form appropriate to US practice and to remove multiple dependencies for the purpose of reducing fees.

Applicants have amended the specification for purposes of adding the priority information. Applicants have attached an Abstract on a separate sheet of paper as required by US practice.

Entry of the amendment prior to the examination of the application and calculation of the filing fee is respectfully requested.

The Commissioner is hereby authorized in this, concurrent, and future replies, to charge any fees or credit any overpayment, particularly including any fees required under 37 CFR Sect 1.16 or 1.17, and any necessary extension of time fees, to deposit Account No. 07-1392.

Respectfully submitted,

Viriginla)G. Carhpen Attorney for Applicant

Registration No. 37,092

Date: 19 Sept. 05

GlaxoSmithKline

Corporate Intellectual Property

Five Moore Drive P.O. Box 13398

Research Triangle Park, NC 27709-3398

Phone: 919-483-1012 Facsimile: 919-483-7988